272 Capital LP 13D and 13G filings for Harvard Bioscience, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 12:31 pm Sale |
2024-09-30 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 1,555,820 3.600% |
-1,383,458 (-47.07%) |
Filing |
| 2024-02-14 08:46 am Sale |
2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 2,939,278 6.900% |
-325,518 (-9.97%) |
Filing |
| 2023-02-16 3:11 pm Unchanged |
2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 3,264,796 7.800% |
0 (Unchanged) |
Filing |
| 2023-02-15 5:30 pm Purchase |
2022-11-29 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 3,264,796 7.840% |
3,264,796 (New Position) |
Filing |